A Powerful Solution for More Accurate COVID-19 Antibody Detection LABScreen™ COVID Plus

Detect COVID-19 Antibodies for a More Complete Antibody Profile

Research has identified five antibodies, which are developed in response to portions of two COVID-19 antigens, that may be useful for providing a broader picture of the humoral response.

About two weeks after infection, antibodies will present at detectable levels. Many COVID-19 antibody tests are designed to detect 1-2 antibodies, which can indicate whether a patient has been exposed to the virus and may provide sufficient information for the general population.

However, transplant patients and potential living donors need more clarity. A broader view of the immune response may clarify whether the patient has developed protective antibodies to the COVID-19 virus and may reveal if the patient's HLA antibody profile has changed, as can happen with similar viral infections(1).

  • Comprehensive SARS-CoV-2 specific multiplex antibody detection panel
  • Luminex xMAP based assay optimized for the LABScan 200 and LABScan 3D

CE IVD – European Union Only.

Assay Indicates the Presence of Five SARS-CoV-2 Targets

A Multiplex Bead-Based Solution for COVID-19 Antibody Detection

The LABScreen™ COVID Plus assay is the most comprehensive COVID-19 antibody test with five unique targets and, along with HLA antibody testing, is designed to deliver a complete picture of the patient's antibody profile.

Using Luminex's xMAP technology, this multiplex semi-quantitative assay can simultaneously detect the presence of 5 SARS-CoV-2 targets present in a patient's blood: the spike, S1, S2, receptor-binding domain, and nucleocapsid fragments.

For informational purposes only, the panel also includes additional targets for seasonal coronaviruses, SARS, and MERS, which may be cross reactive and cause false positives in other tests.

The assay was developed by leading researchers in histocompatibility, nephrology, transplantation, and infectious diseases to provide deeper insight into the immune response to SARS-CoV-2. Turaround time for the assay, which can be run in parallel with our LABScreen Single Antigen panel, is two to three hours.

It all starts with a demo
Click here to request a demo for LABScreen Autoantibody
Want to see a list of available products?
Click here to view the product details


Educational Resources about LABScreen COVID Plus

Use the filters below to browse available events & on-demand resources.

FILTERS Clear all
Resource Type
COVID Plus: A New Diagnostic Tool to Protect Transplant Patients in the Fight Against COVID-19
Published: MAR 2, 2021
Identifying multiple distinct antibodies to COVID-19 will be vitally important as some have demonstrated neutralizing capabilities
Immune Response to COVID-19 and Vaccination in Transplant Patients
Recorded: MAR 19, 2021
The COVID-19 pandemic has impacted the transplant community disproportionately and remains an important topic in the field of histocompatibility and immunology.
Multiplexed SARS CoV2 Platforms: Future Interactions
Recorded: AUG 25, 2020
Dr. Woodle reviews the body of evidence that suggests SARS-CoV-2 may circumvent many of the typical rules of immune response and discusses the research applications for a multiplex assay as a tool.
What is the LABScreen™ COVID Plus Assay?
Recorded: AUG 25, 2020
Dr. Bray explains how the assay will allow labs to examine the heterogeneity of humoral responses between patients as well as the development of the humoral response in a single patient over time.
Cinical Utility of SARS-CoV-2 Antibody Testing
Recorded: AUG 25, 2020
Dr. Deepali Kumar examines how a multi-antigen assay can help characterize vaccine response and clarify how antibodies present in asymptomatic versus symptomatic patients.
Testing for SARS-CoV-2 Antibodies: How it began
Recorded: AUG 25, 2020
Dr. Howard Gebel shares the need for an assay that is comprehensive, specific, and sensitive enough to build a complete antibody profile for patients exposed to the COVID-19 virus.
Assessment of the Humoral Response to SARS-CoV-2 Infection Via Novel Multiplexed Assays
Recorded: OCT 18, 2020
Discussion on what we currently know about the humoral response to the SARS-CoV-2 virus and explore the clinical and research applications of using a multiplexed assay to test for COVID-19 antibodies.
  1. Locke JE, Zachary AA, Warren DS, et al. (2009) Proinflammatory events are associated with significant increases in breadth and strength of HLA-specific antibody. Am J Transplant. 9(9):2136-2139. doi:10.1111/j.1600-6143.2009.02764.